IJACT, Volume 3, Issue 10, 2025 ISSN: 2995-5378
http://medicaljournals.eu/index.php/IJACT
INTERNATIONAL JOURNAL OF ALTERNATIVE AND CONTEMPORARY THERAPY

The Relevance of Improving Measures for the Treatment of Tuberculosis of Peripheral Lymph Nodes

N. N. Parpieva [1], A. A. Adilkhodjaev [2], Z. A. Mo'minova [3]

[1] Doctor of Medical Sciences, director of Ministry of Health of the Republic of Uzbekistan, Republican Specialized Scientific and Practical Medical Center of Phthisiology and Pulmonology named after Academician Sh. Alimov. Republic of Uzbekistan, Tashkent city.

[2] Doctor of Medical Sciences, Scientific director of the Department of Extrapulmonary Organ Surgery of Ministry of Health of the Republic of Uzbekistan, Republican Specialized Scientific and Practical Medical Center of Phthisiology and Pulmonology named after Academician Sh. Alimov. Republic of Uzbekistan, Tashkent city.

[3] PhD of Ministry of Health of the Republic of Uzbekistan, Republican Specialized, Scientific and Practical Medical Center of Phthisiology and Pulmonology named after Academician Sh. Alimov. Republic of Uzbekistan, Tashkent city

Abstract: When it comes to treatment resistance, new infections, poor patient compliance, and adverse medication reactions, PR are more common in LNTB than in pulmonary tuberculosis. Despite the fact that the discovery of endosonography has greatly simplified the diagnosis of mediastinal LNTB, little is known about this condition. Investigating the clinical course of mediastinal LNTB and the risk variables linked to PR was the goal of this investigation. The mainstay of treatment for peripheral lymph node TB is a multi-drug anti-tuberculosis chemotherapy regimen, which typically lasts six months to a year and includes medications like rifampin and isoniazid. To lessen complications and enhance quality of life, surgery may also be considered for bigger nodes, abscesses, fistulas, or cases of treatment resistance and recurrence. To increase the body's resistance and stop recurrence, it's also critical to support general health through diet and exercise. Between 13.3% and 35.3% is the range of prevalences of PR linked to LNTB. PR can happen during antitubercular therapy or even after treatment is over; this is known as post-therapy PR. A PR onset might happen as soon as one month into treatment or as long as a year after starting an anti-tubercular medication. It is thought that a PR may result from a delayed hypersensitivity reaction and a decrease in immunological suppression. A nodal enlargement that already exists or the development of an abscess, sinus, or new nodal enlargement, or in rare cases, extra-nodal involvement, are the hallmarks of PR in LNTB. Granuloma, a positive acid-fast bacilli (AFB) smear, or a positive GeneXpert can all be signs of PR, an exclusionary diagnosis, but the AFB culture is usually negative.

Keywords: paradoxical responses, pulmonary tuberculosis, anti-tubercular medication, immunological suppression, antitubercular therapy, tubercular lymphadenitis.

Introduction. The most prevalent type of extra-pulmonary tuberculosis (EPTB) in both HIV-positive and non-infected patients is peripheral lymph node tuberculosis (PLNTB). The most commonly impacted area is the cervical region. The most frequent culprit is Mycobacterium tuberculosis. Young adults who are economically productive and female are more likely to be impacted. Although recurrent evacuation of the afflicted node is occasionally necessary to prevent scar formation, surgical excision is linked to a somewhat worse prognosis than medical treatment alone, making tubercular lymphadenitis mostly a medical illness. However, despite medical treatment, many of these individuals have sinus formation, an increase in the size of pre-existing lesions, or the advent of new lymph nodes or diseases. This becomes more difficult while treating cervical lymph node tuberculosis (CLNTB), a cosmosensitive region [1-4]. *Mycobacterium tuberculosis* (MTB) causes extrapulmonary tuberculosis

(EPTB), an infectious disease that affects organs other than the lungs. Of the 6.4 million cases that were recorded in 2021, 17% were due to EPTB; this percentage varied from 8% in the Western Pacific Region to 23% in the Eastern Mediterranean Region. About 20 to 40 percent of all cases of EPTB manifest as lymph node tuberculosis (LNTB), making it one of the most prevalent presentations. Because peripheral lymph nodes (LNs) are simpler to identify and reach, most prior research on LNTB examined peripheral LNTB rather than mediastinal LNTB. When a patient has been receiving anti-tuberculosis (TB) treatment for at least two weeks—aside from documented relapse or the presence of another disease—a paradoxical reaction (PR) occurs when pre-existing disease worsens or new lesions form. Between three weeks and four months after starting anti-TB treatment, the majority of PR cases in patients with peripheral LNTB present as enlarged LNs, new afflicted nodes, discomfort, and sinus drainage. The significance of differentiating between drug resistance, new infections, poor patient compliance, and adverse drug reactions is illustrated by this phenomenon. Furthermore, a PR happens rather frequently—roughly 20% of patients with peripheral LNTB during anti-TB treatment—as opposed to less than 5% of pulmonary TB cases in patients who are HIV-negative [5-11]. Despite the fact that endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has greatly simplified the diagnosis of mediastinal LNTB, little is known about this procedure. Investigating the clinical course of mediastinal LNTB and the risk variables linked to PR was the goal of this investigation. The small sample size and inadequate investigation of unique treatment responses, such as paradoxical responses, were the study's primary weaknesses. This investigation, however, focuses on a particular institution. Nonetheless, the findings are positive and offer a solid foundation for further research. In order to conduct additional research, we will aim to collaborate with other institutions and gather more examples. In conclusion, multimodal ultrasound can offer detailed information about how CTL react to anti-TB treatment. Along with the lymph node's size change, other factors that are linked to a poor prognosis include the presence of internal pus or non-enhancement area enlargement, enhanced echo of the surrounding tissue, and enlargement following CEUS. These factors may also be used to assess how well anti-tuberculosis chemotherapy is working when the lymph node's size change is not evident during individual treatment [12-17].

The main purpose of this review is a brief analysis of the relevance of improving therapeutic measures for tuberculosis of peripheral lymph nodes with the help of reputable scientific research.

Study up on lymphadenopathy. Women are twice as likely as males to get lymphatic TB, which is prevalent in adolescents, particularly children. Lymphatic tuberculosis typically manifests in the groin, armpits, and neck. In other instances, internal organs including the mediastinal and mesenteric lymph nodes may develop lymphatic tuberculosis. The illness is frequently linked to TB of the lungs or adjacent organs. Deep lymphatic tuberculosis and peripheral lymphatic tuberculosis are the two types of lymphatic tuberculosis. The primary cause of this illness is the entry of tuberculosis bacteria into the body through many pathways, including infections, oral mucosa, and trauma. Rarely does lymphatic tuberculosis manifest in the groin, whereas it frequently occurs in the neck. Over time, enlarged lymph nodes are common in people with lymphatic tuberculosis. The lymph nodes become uncomfortable, enlarge, and become unequal in size over time. The patient may also experience rapid weight loss, exhaustion, and an afternoon temperature. Ultrasound, fine needle aspiration, biopsy or sputum, blood, and PCR tests are used to identify tuberculosis of the lymph nodes [7-12].

Treatment of lymph node tuberculosis that works. Coordination between the patient and the physician is necessary throughout the treatment of lymph node TB. Depending on how persistent the patient is, the course of treatment may be quick or drawn out. Patients with lymph node tuberculosis who receive active treatment can reduce their risk of developing tuberculosis sequelae. The following approaches are currently used to treat lymph node tuberculosis: Internal medicine: Patients must do as their doctor directs. Take the medication as prescribed, at the appropriate time, and most importantly, don't stop midway. For lymph node TB, internal medicine treatment lasts for around eight months. Approximately three months are dedicated to treating attacks, followed by maintenance [1,2,3]. The patient may observe an improvement in their health throughout the initial phases of treatment. To get the best outcomes and avoid recurrence, the patient must finish the 8-month course of treatment.

Surgical intervention: The physician will remove the lymph nodes surgically. But not every patient is able to apply this technique. Surgery is typically recommended for conditions like non-suppurative lymphadenopathy and lymphadenopathy associated with tuberculosis. In summary, basic anti-tuberculosis medications can be used to treat lymphadenopathy if there are no problems. The patient's cooperation during treatment is crucial in this situation. To reduce the chance of lymphadenopathy forming and returning, patients must also increase their resistance through frequent exercise and nutritional supplements [7,8,9].

Therefore, it appears that QC, including QC-based AI, will play a significant role in medical imaging and healthcare in general in the future. We can only make educated guesses about the possible uses of this "work in progress" technology. More complex activities can be dreamed of because of the astounding increase in computer power, which will allow previously unthinkable jobs to be completed in a "jiffy." We can anticipate the development of quantum artificial intelligence algorithms and similar technologies. As QC develops, the Metaverse will provide a more immersive experience for both teaching and simulation as well as real-world interactions by providing visualizations and perspectives that would not have been possible otherwise. Augmented reality and virtual reality, particularly for teaching and simulations, have enormous potential for medical imaging in tuberculosis, community involvement, and other applications, as well as for improving adherence to TB guidelines and norms (see the section above on Augmented Reality &/Virtual Reality) [9-16]. Although we have covered a wide range of technologies that function at subatomic and human scales, the main obstacle to using them to eradicate tuberculosis is incorporating them into a comprehensive strategy. For instance, AI cannot function in a vacuum; it requires vast amounts of patient and population-level data. It will be far more beneficial if it incorporates data from new imaging modalities or translational applications of bench-science research (such as the detection of resistance mutations through PCR, which can optionally be enhanced by CRISPR). Policies created by the concerted efforts of international consortia that use a variety of global skills, including that provided by cutting-edge technologies, must serve as the foundation for the integration [17-25].

Discussion. The clinical course of mediastinal LNTB, the prevalence of PR in patients with mediastinal LNTB, and risk variables linked to PR were all examined in this retrospective observational analysis. Of the 125 patients in our trial, 21 (17%) experienced PR at a median of 4.4 months following the start of anti-TB medication. Multivariable logistic regression analysis revealed that PR was independently linked to lymphocytopenia, bigger LN, and younger age. As far as we are aware, this is the first study to outline the clinical progression of mediastinal LNTB as well as the traits of PR in this condition. Prior to the creation of EBUS-TBNA, mediastinal LNs may be sampled using a number of methods, such as mediastinoscopy, transesophageal ultrasound-guided needle aspiration, CT-guided percutaneous needle aspiration, and traditional transbronchial needle aspiration [1,4,9]. Although it has certain drawbacks, mediastinoscopy has traditionally been the recommended technique for acquiring specimens from mediastinal LNs. It is a costly, invasive surgical treatment with a 1–2% morbidity rate that necessitates general anesthesia. Furthermore, the hilar and posterior subcarinal nodes are typically inaccessible. A minimally invasive method that provides access to nodes frequently impacted by tuberculosis, EBUS-TBNA is currently in widespread use. According to earlier research, EBUS-TBNA is a safe and efficient treatment for mediastinal LNTB. However, as was the case prior to the development of EBUS-TBNA, the clinical course of mediastinal LNTB has not been well documented. The current investigation presented comprehensive clinical data, including symptoms, concomitant TB, medication resistance, mechanical problems, and PR, and examined the greatest number of patients with mediastinal LNTB to date [18-22]. In order to diagnose PR, it is necessary to assess whether appropriate anti-TB treatment has been given and whether drug resistance or other illnesses have been ruled out. Invasive procedures are frequently necessary when PRs are suspected in individuals with EPTB, and DST is more challenging than for pulmonary TB. Since diagnosing PRs in patients with EPTB is frequently difficult in real-world clinical settings, decisions are typically based on clinical and radiological advancements while continuing anti-TB therapy. Our research identified risk variables and CT results that aid physicians in identifying the PR. We discovered that not all LNs

degraded at the same time in PR scenarios, and only a small percentage of LNs were noticeably enlarged. Furthermore, greater LN sizes were associated with a higher likelihood of the PR, which is in line with earlier findings on peripheral LNTB [23,24]. Although radiologic and pathologic findings are consistent with TB, the presence of residual LNs after 6 months of antituberculous treatment in patients with CTBL does not necessarily indicate recurrence or treatment failure. In younger patients, residual LNs might still be present six months after treatment, and following brief observation, reevaluation might be taken into consideration. A six-month antituberculous therapy may be adequate, according to this study, which suggested that the lengthy treatment duration that has been frequently seen in patients with residual LNs should be reexamined [11-18].

Conclusion. The clinical, radiologic, and pathologic results of a six-month course of treatment for tuberculous lymphadenitis are presented in this study. The following are the study's limitations: Some of the specimens were unsuitable, and not all patients with remaining LNs had FNAB. The majority of patients with remaining LNs received antituberculous medication for longer than six months, and CT images were not acquired throughout the subsequent follow-up period. The next step is to determine the factors associated with TB recurrence in the remaining LN group. For there to be statistical significance, more follow-up research involving a larger patient population is required.

One of the most common clinical manifestations of extrapulmonary TB, especially in young people and women, is tuberculosis lymphadenitis. Most often, cervical lymph nodes are involved, and FNAC is a useful first diagnostic method. Most patients respond favorably to conventional anti-tubercular treatment. For positive results and the reduction of problems, early diagnosis, suitable intervention, and consistent follow-up are crucial.

Even while radiologic and pathologic features are consistent with TB, the presence of residual LNs in patients with CTBL after 6 months of antituberculous treatment does not always imply recurrence or treatment failure. After six months of treatment, residual LNs may still be present in younger individuals, and reevaluation may be warranted following brief surveillance. According to this study, a six-month antituberculous therapy might be adequate, and the lengthy treatment duration that has been frequently seen in patients with residual LNs should be reexamined.

References.

1. The prevalence, risk factors, and public health consequences of peripheral lymph node–associated clinical and subclinical pulmonary tuberculosis. Heffernan, Courtney et al. International Journal of Infectious Diseases, Volume 129, 165 – 174.
2. Is tuberculous lymphadenopathy dangerous? 2025. https://www.vinmec.com/eng/blog/tuberculosis-is-dangerous-en
3. Prahlad Rai Gupta. Role of Add-on Prednisolone in the Management of Peripheral Lymph Node Tuberculosis. Journal of Infectiology and Epidemiology. https://doi.org/10.29245/2689-9981/2018/2.1115
4. Choe J, Han A, Shin SH, Lee K, Um SW, Kim H, Kim TY, Huh HJ, Choi YL, Han J, Jeong BH. Clinical Course of Patients With Mediastinal Lymph Node Tuberculosis and Risk Factors for Paradoxical Responses. J Korean Med Sci. 2023 Nov;38(47):e348. https://doi.org/10.3346/jkms.2023.38.e348
5. "Paradoxical Reaction in Peripheral Lymph Node Tuberculosis: A Review of Its Prevalence, Clinical Characteristics, and Possible Treatment". 2023. Monaldi Archives for Chest Disease 94 (3). https://doi.org/10.4081/monaldi.2023.2625.
6. Rai DK, Kumar R, Ahmad S. Clinical characteristics and treatment outcome in tubercular lymphadenitis patients- A prospective observational study. Indian J Tuberc 2020;67:528-33.
7. Takahashi S, Otomo K, Kawakami Y, Nakamura M. Uveitis developing in tuberculous lymphadenitis-associated Behçet's disease during anti-tuberculosis therapy. Respirol Case Rep 2020;8:e00617.

8. Lakshmi VP, Abhinandh B, Kunoor A, et al. Paradoxical reaction in lymph node tuberculosis presented as shoulder osteomyelitis. J Pharmacol Pharmacother 2021;12:140-3.
9. Complications of Lymph Tuberculosis. 2024, https://www.vinmec.com/eng/blog/complications-of-lymph-node-tuberculosis-en
10. Kulchavenya E.V., Koveshnikova E.Yu., Merganov M.M., Sharipov F.R. Peripheral lymph node tuberculosis: epidemiological characteristics. Tuberculosis and Lung Diseases. 2018;96(10):30-34. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-10-30-34
11. Ko RE, Jeong BH, Chon HR, Huh HJ, Han J, Lee H, et al. Clinical usefulness of routine AFB culture and MTB PCR of EBUS-TBNA needle rinse fluid. Respirology 2019;24(7):667–674.
12. Holden IK, Lillebaek T, Andersen PH, Bjerrum S, Wejse C, Johansen IS. Extrapulmonary tuberculosis in Denmark from 2009 to 2014; characteristics and predictors for treatment outcome. Open Forum Infect Dis 2019;6(10):ofz388
13. Lucey O, Potter J, Ricketts W, Castle L, Melzer M. Utility of EBUS-TBNA in diagnosing mediastinal tuberculous lymphadenitis in East London. J Infect 2022;84(1):17–23.
14. Mathiasen VD, Eiset AH, Andersen PH, Wejse C, Lillebaek T. Epidemiology of tuberculous lymphadenitis in Denmark: a nationwide register-based study. PLoS One 2019;14(8):e0221232
15. Nie D, Li J, Liu W, Wu Y, Ji M, Wang Y, et al. Esophagomediastinal fistula due to secondary esophageal tuberculosis: report of two cases. J Int Med Res 2021;49(7):3000605211023696
16. Barss L, Connors WJ, Fisher D. Chapter 7: extra-pulmonary tuberculosis. Canadian Respir Crit Care Sleep Med 2022;6(sup1):87–108.
17. Sharma, SK, Mohan, A, and Kohli, M. Extrapulmonary tuberculosis. Expert Rev Respir Med. (2021) 15:931–48. doi: 10.1080/17476348.2021.1927718
18. Ganchua, SKC, White, AG, Klein, EC, and Flynn, JL. Lymph nodes-the neglected battlefield in tuberculosis. PLoS Pathog. (2020) 16:e1008632. doi: 10.1371/journal.ppat.1008632
19. Lekhbal, A, Chaker, K, Halily, S, Abada, RL, Rouadi, S, Roubal, M, et al. Treatment of cervical lymph node tuberculosis: when surgery should be performed? A retrospective cohort study. Ann Med Surg. (2020) 55:159–63. doi: 10.1016/j.amsu.2020.05.006
20. Strassen, U, Geisweid, C, Hofauer, B, and Knopf, A. Sonographic differentiation between lymphatic and metastatic diseases in cervical lymphadenopathy. Laryngoscope. (2018) 128:859–63. doi: 10.1002/lary.26837
21. Zhang, Y, Yu, T, Su, D, Tang, W, and Yang, G. Value of contrast-enhanced ultrasound in the ultrasound classification of cervical tuberculous lymphadenitis. Front Med. (2022) 9:898688. doi: 10.3389/fmed.2022.898688
22. Yu, TZ, Zhang, Y, Zhang, WZ, and Yang, GY. Role of ultrasound in the diagnosis of cervical tuberculous lymphadenitis in children. World J Pediatr. (2021) 17:544–50. doi: 10.1007/s12519-021-00453-w
23. Zhao, D, He, N, Shao, YQ, Yu, XL, Chu, J, and Yang, G. The diagnostic value of contrast-enhanced ultrasound for cervical tuberculous lymphadenitis. Clin Hemorheol Microcirc. (2022) 81:69–79. doi: 10.3233/CH-211355
24. Yu T, Zhang L, Xu J, Meng J, Yu X and Zhang Y (2023) The value of multimodal ultrasonography in evaluating therapeutic response of cervical tuberculous lymphadenitis to anti-tuberculosis drugs. Front. Med. 10:1177045. doi: 10.3389/fmed.2023.1177045
25. Merchant SA, Shaikh MJS, Nadkarni P. Tuberculosis conundrum - current and future scenarios: A proposed comprehensive approach combining laboratory, imaging, and computing advances. World J Radiol. 2022 Jun 28;14(6):114-136. doi: 10.4329/wjr.v14.i6.114.